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Key messages
What is the key question?
 ► Is it possible to predict prognosis in patients with 
malignant pleural mesothelioma (MPM) using data 
collected routinely during patient care?
What is the bottom line?
 ► In patients with a confirmed diagnosis of MPM, risk 
of death at 6 months can be predicted using vari-
ables readily available in clinical practice.
Why read on?
 ► The risk prediction model we have developed could 
be used to influence treatment decisions in patients 
with MPM.
AbstrAct
Introduction The prognosis of malignant pleural 
mesothelioma (MPM) is poor, with a median survival 
of 8–12 months. The ability to predict prognosis in 
MPM would help clinicians to make informed decisions 
regarding treatment and identify appropriate research 
opportunities for patients. The aims of this study were to 
examine associations between clinical and pathological 
information gathered during routine care, and prognosis 
of patients with MPM, and to develop a 6- month mortality 
risk prediction model.
Methods A retrospective cohort study of patients 
diagnosed with MPM at Queen Alexandra Hospital, 
Portsmouth, UK between December 2009 and September 
2013. Multivariate analysis was performed on routinely 
available histological, clinical and laboratory data to assess 
the association between different factors and 6- month 
survival, with significant associations used to create a 
model to predict the risk of death within 6 months of 
diagnosis with MPM.
results 100 patients were included in the analysis. 
Variables significantly associated with patient survival in 
multivariate analysis were age (HR 1.31, 95% CI 1.09 to 
1.56), smoking status (current smoker HR 3.42, 95% CI 
1.11 to 4.20), chest pain (HR 2.14, 95% CI 1.23 to 3.72), 
weight loss (HR 2.13, 95% CI 1.18 to 3.72), platelet count 
(HR 1.05, 95% CI 1.00 to 1.10), urea (HR 2.73, 95% CI 1.31 
to 5.69) and adjusted calcium (HR 1.47, 95% CI 1.10 to 
1.94). The resulting risk model had a c- statistic value of 
0.76. A Hosmer- Lemeshow test confirmed good calibration 
of the model against the original dataset.
conclusion Risk of death at 6 months in patients with 
a confirmed diagnosis of MPM can be predicted using 
variables readily available in clinical practice. The risk 
prediction model we have developed may be used to 
influence treatment decisions in patients with MPM. 
Further validation of the model requires evaluation of its 
performance on a separate dataset.
IntroductIon
Malignant pleural mesothelioma (MPM) is a 
rare cancer predominantly caused by asbestos 
which affects the pleura, a thin membrane 
of cells which lines the lungs and chest wall.1 
The prognosis of MPM is generally regarded 
as poor, with a median survival of between 8 
and 12 months.2 The UK currently has the 
highest death rate from MPM in the world,3 
with approximately 2500 deaths per year.4 
The ability to predict prognosis in MPM 
would help clinicians to make informed deci-
sions regarding treatment, tailored to indi-
vidual patients, such as early specialist palli-
ative care.5 Predicting prognosis also enables 
clinicians to identify appropriate research 
opportunities for patients.
There exists a large body of evidence exam-
ining prognostic factors in MPM including 
numerous clinical factors such as basic 
epidemiological variables, clinical condition, 
imaging assessments and tumour features.6–9 
Several prognostic scoring systems have been 
developed for MPM by combining prognostic 
variables, such as the European Organisation 
for Research and Treatment of Cancer6 and 
Cancer and Leukaemia Group B7 prognostic 
scoring systems, but these were derived from 
large series of patients from chemotherapy 
trials and may not reflect ‘real- world’ unse-
lected patient cohorts. The LENT score is a 
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Table 1 Potential predictor variables for survival in 
patients diagnosed with malignant pleural mesothelioma in 
Portsmouth, UK
Group Variable





Body mass index (BMI)
Any known history of asbestos 
exposure
Smoking status at diagnosis 
(never smoker, ex- smoker, current 
smoker)




Diagnosed non- respiratory 
comorbidity
Total no of comorbidities








Cytology—presence of malignant 
cells
Haematology Haemoglobin (Hb)
Red cell distribution and width 
(RDW)
Platelet count (PLT)
Systemic inflammation White blood cell count (WCC)
Neutrophil lymphocyte ratio (NLR)





Liver function Total protein
Albumin
Alkaline phosphatase (ALP)






prognostic scoring system for patients with malignant 
pleural effusions including mesothelioma10; however, 
this system is not specific for predicting survival in MPM 
and may not be applicable to patients with MPM without 
evidence of an effusion. More recently, a clinical predic-
tion model for prognosis in MPM has been developed 
using survival at 18 months as the dependent variable11 
using routinely available histological, clinical and labora-
tory information. However, since the median survival in 
patients with MPM is considered to be 8–12 months from 
diagnosis, identifying patients with an expected prog-
nosis beyond 6 months would potentially be of greater 
value in guiding treatment decisions.
This study evaluated the Portsmouth city population, 
an area within close proximity of a dockyard with a 
historically large shipbuilding industry, where a signifi-
cant amount of asbestos was used. As a result, the prev-
alence of asbestos- related respiratory disease including 
MPM among the local population is significantly greater 
than the UK average,12 13 with approximately 30 to 40 
new cases of MPM diagnosed each year in Portsmouth. 
Optimal prognostication is therefore of particular impor-
tance in order to respond to the needs of the local popu-
lation. The aim of this study was to identify clinical and 
pathological characteristics gathered during routine 
care, including demographic and clinical information, to 
predict risk of death in an unselected group of patients 
with MPM. These data were then studied for an associa-
tion with outcomes and used to develop a mortality risk 
prediction model.
Methods
This was a retrospective cohort study of 100 consecu-
tive patients aged over 18 years diagnosed with MPM at 
Queen Alexandra Hospital, Portsmouth, UK between 
December 2009 and September 2013. Data were collated 
from a pre- existing database, originally designed to eval-
uate the clinical services and patient pathway provided 
by the MPM service at Portsmouth. Identifiable patient 
information from the original database was anonymised 
for the purposes of the study. The dataset was censored 
for survival on 31 October 2014.
The outcome variable was patient survival time, 
measured as the time from the date of MPM diagnosis 
to the date of death. Potential predictor variables were 
chosen following a review of current literature,6–9 13–17 
selected from data that are routinely available at the 
point of diagnosis including demographic characteristics 
and laboratory test results. These variables are listed in 
table 1. We did not adjust patient survival for treatment 
given the multitude of factors that influence treatment 
decisions, variation in treatment regimens and since the 
improvement in survival was thought to be modest.
statistical approach
A description of the study cohort for all potential risk 
factors was provided using mean and SD for continuous 
variables with a normal distribution, median and IQR 
for continuous variables with a skewed distribution, 
and frequency and percentage for categorical variables. 
As some patients in the study were still alive at time of 
data collection, it was necessary to analyse the data using 
survival analysis methods including Kaplan- Meier plots. 
All analyses were performed using Cox regression.
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Table 2 Demographics of 100 consecutive patients 
diagnosed with malignant pleural mesothelioma in 














  Male (n (%)) 85 (85%)
  Female (n (%)) 15 (15%)
Weight (kg) (mean±SD) 70 74.8±16.8
BMI (kg/m2) (mean±SD) 48 26.0±4.9
Asbestos exposure 89
  Yes (n (%)) 69 (78%)
  No (n (%)) 20 (22%)
Smoking status 94
  Non- smoker (n (%)) 25 (27%)
  Ex- smoker (n (%)) 57 (61%)
  Current smoker (n (%)) 12 (13%)
Performance status (PS) 95
  0 (n (%)) 24 (25%)
  1 (n (%)) 43 (45%)
2+ (n (%)) 28 (29%)
Comorbidities 98
Respiratory comorbidity (n (%)) 17 (17%)
Non- respiratory comorbidity (n 
(%))
69 (70%)
Total no of comorbidities
  0 (n (%)) 24 (24%)
  1 (n (%)) 39 (40%)
2+ (n (%)) 35 (36%)
Dyspnoea (n (%)) 99 84 (85%)
Chest pain (n (%)) 99 43 (43%)
Cough (n (%)) 99 55 (56%)
Weight loss (n (%)) 99 51 (52%)
Loss of appetite (n (%)) 99 45 (45%)
Night sweats (n (%)) 99 13 (13%)
Fever (n (%)) 99 2 (2%)
Histological subtype 94
  Epithelioid (n (%)) 63 (67%)
  Sarcomatoid (n (%)) 21 (22%)
  Unclassified (n (%)) 10 (11%)
Malignant cells (cytology) (n (%)) 65 18 (28%)










RDW % (median (IQR)) 99 14.1 (13.2 
to 15.3)
PLT ×109/L (mean±SD) 99 340±114
WCC ×109/L (median (IQR)) 99 9.2 (8.1 to 
11.7)
NLR (median (IQR)) 99 5.2 (3.4 to 
7.6)
CRP mg/L (median (IQR)) 66 48 (15 to 
80)
Urea mmol/L (median (IQR)) 98 4.7 (4.0 to 
6.2)
Na mmol/L (mean±SD) 98 136±3
K mmol/L (mean±SD) 96 4.4±0.4
Creatinine µmol/L (median (IQR)) 98 81 (67 to 
94)
Total protein g/L (mean±SD) 92 66.9±6.1
Albumin g/L (mean±SD) 92 32.9±5.0
ALP IU/L* (median (IQR)) 92 73 (56 to 
92)
Adjusted calcium mmol/L (median 
(IQR))
80 2.32 (2.26 
to 2.39)
Phosphate mmol/L (mean±SD) 77 1.16±0.23
Pleural fluid protein g/L 
(mean±SD)
49 43.7±8.9
Pleural fluid LDH IU/L* (median 
(IQR))
52 701 (488 to 
1376)
Categorical variables are summarised by the number and 
percentage. Continuous variables with a normal distribution are 
summarised by the mean and SD. Continuous variables with a 
skewed distribution are summarised by the median and IQR.
*International units per litre.
Table 2 Continued
Univariate analysis was first performed to assess the 
association between each factor and survival. Where a 
linear relationship was not found to be appropriate, a 
non- linear relationship between the variable and the risk 
of death was assumed. The joint association between the 
variables and the outcome was then assessed in a multi-
variate analysis; only variables showing some evidence of 
an association with survival from the univariate analyses 
(p<0.1) were included. Variables with incomplete data 
were also excluded from the multivariate analysis.
The variables identified to be significant in the multi-
variable regression analysis were then used to create a 
risk model to predict the probability of death within 6 
months of diagnosis for each patient. A 6- month cut- off 
was used, as it would allow for better treatment planning 
in a patient group where median survival is considered to 
be 8–12 months from diagnosis.
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Figure 1 Kaplan- Meier plot of survival times of all 100 
patients with mesothelioma.
The linear combination of the coefficients was initially 
calculated. For categorical variables, the coefficient was 
added to the total if that factor was present. For contin-
uous variables, the coefficient was multiplied by the 
value for that factor. Once the linear combination was 
calculated, a transformation was required to obtain the 
predicted probability.





p=Predicted risk of death at 6 months.
exp=exponential function.
Two aspects of the model performance were then eval-
uated. First, the discrimination of the model was eval-
uated using Harrell’s C- statistic, broadly equivalent to 
the area under the ROC curve, examining the ability of 
the model to distinguish between high- risk and low- risk 
cases. Second, both the discrimination and calibration 
of the model was examined by dividing the predicted 
risk into three categories, each chosen to give a reason-
ably similar number of patients in each category. The 
observed percentage of graft loss within each of these 
three categories was calculated and this was compared 
with the predicted risk. The calibration of the model was 
also examined by the use of the Hosmer- Lemeshow test, 
comparing the observed and predicted number of events 
and non- events in the same categories.
Data were analysed using IBM SPSS statistical package 
V.22.0.
ethical approval
As all patients in this study remained anonymous, we did 
not require individual consent in accordance with the 
Medical Research Council.18
Patient and public involvement
Opinion and feedback on study design was sought 
through the Hampshire Asbestos Support and Aware-
ness Group (HASAG), a charity based in Hampshire, UK 
that supports people affected with MPM and their fami-
lies. HASAG will also be involved in dissemination of the 
results via their newsletter and website.
results
Data from a total of 100 consecutive patients diagnosed 
with MPM were included. Variables were collected within 
2 weeks of initial presentation for all patients, apart from 
histological confirmation: histology was available for 92 
patients at the time of diagnosis; two further patients 
received a cytological diagnosis; six patients received a 
radiological diagnosis, later confirmed on post mortem. 
The median time from first presentation to date of diag-
nosis was 14 days (IQR 8–50 days). Patient demographics 
and variables are summarised in table 2.
The primary outcome was patient survival: the 1- year 
survival was 26% (95% CI 18% to 35%). A graphical illus-
tration of the survival times of the whole cohort is given 
in a Kaplan- Meier plot (figure 1).
univariate analysis
The association between each factor and survival was first 
examined in a series of univariate analyses (table 3). The 
size of the association between each predictor variable 
and survival was quantified using HRs, along with corre-
sponding CIs.
When examined separately, a number of the vari-
ables were significantly associated with patient survival: 
age (HR 1.07, 95% CI 1.00 to 1.14), weight (HR 0.82, 
95% CI 0.70 to 0.95), body mass index (BMI) (HR 0.71, 
95% CI 0.52 to 0.96), smoking status (HR 2.20, 95% CI 
1.07 to 4.51), performance status greater than 1 (HR 
3.21, 95% CI 1.80 to 5.74), dyspnoea (HR 0.49, 95% CI 
0.27 to 0.86), chest pain (HR 1.60, 95% CI 1.05 to 2.43), 
weight loss (HR 2.37, 95% CI 1.55 to 3.62), haemoglobin 
(HR 0.77, 95% CI 0.68 to 0.88), platelet count (HR 1.04, 
95% CI 1.01 to 1.07), urea (HR 1.31, 95% CI 1.03 to 
1.67), potassium (HR 2.21, 95% CI 1.09 to 4.49), creati-
nine (HR 40 042, 95% CI 9.2 to 1 768 852), albumin (HR 
0.70, 95% CI 0.55 to 0.88), adjusted calcium (HR 1.37, 
95% CI 1.10 to 1.70) and pleural fluid LDH (HR 4.26, 
95% CI 1.66 to 11.0).
Multivariate analysis
The second stage of the analysis process examined how 
survival was affected by the variables jointly, in a multi-
variate analysis. As BMI and pleural fluid data were only 
available for 48 and 52 patients, respectively, these varia-
bles were omitted from the analysis. A backwards selec-
tion procedure was performed to retain only the inde-
pendently statistically significant variables. The final 
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es: first published as 10.1136/bm




Gunatilake S, et al. BMJ Open Resp Res 2021;8:e000506. doi:10.1136/bmjresp-2019-000506 5
Open access
Table 3 Summary of the univariate analysis results for the association between the various prognostic factors and survival
Variable N Category/term HR (95% CI) P value
Age at diagnosis* 100 Linear term 1.34 (1.15 to 1.54) <0.001
Squared term 1.07 (1.00 to 1.14)
Gender 100 Male 1 0.93
Female 1.03 (0.59 to 1.79)
Weight† 70 – 0.82 (0.70 to 0.95) 0.009
BMI* 48 – 0.71 (0.52 to 0.96) 0.03
Asbestos exposure 89 No 1 0.36
Yes 1.27 (0.76 to 2.14)
Smoking status 94 Non- smoker 1 0.08
Ex- smoker 1.53 (0.93 to 2.53)
Current smoker 2.20 (1.07 to 4.51)
Performance status (PS) 95 0 1 <0.001
1 1.32 (0.79 to 2.22)
2+ 3.21 (1.80 to 5.74)
Respiratory 98 No 1 0.47
Comorbidity Yes 1.22 (0.72 to 2.07)
Other comorbidity 98 No 1 0.47
Yes 1.18 (0.75 to 1.86)
No of comorbidities 98 0 1 0.12
1 1.10 (0.64 to 1.87)
2+ 1.65 (0.96 to 2.84)
Dyspnoea 99 No 1 0.01
Yes 0.49 (0.27 to 0.86)
Chest pain 99 No 1 0.03
Yes 1.60 (1.05 to 2.43)
Cough 99 No 1 0.72
Yes 0.93 (0.61 to 1.40)
Weight loss 99 No 1 <0.001
Yes 2.37 (1.55 to 3.62)
Loss of appetite 99 No 1 0.15
Yes 1.35 (0.90 to 2.04)
Night sweats 99 No 1 0.36
Yes 1.32 (0.73 to 2.38)
Fever 99 No 1 0.46
Yes 0.59 (0.14 to 2.40)
Histological 94 Epithelioid 1 0.51
Subtype Non- epithelioid 1.20 (0.71 to 2.02)
Unclassified 1.44 (0.73 to 2.83)
Malignant cells (cytology) 65 No 1 0.68
Yes 1.13 (0.63 to 2.00)
Hb 99 – 0.77 (0.68 to 0.88) <0.001
RDW 99 – 1.12 (0.99 to 1.26) 0.07
PLT‡ 99 Linear term 1.02 (0.91 to 1.14) <0.001
Squared term 1.04 (1.01 to 1.07)
WCC 99 – 1.00 (0.94 to 1.07) 0.91
NLR* 99 – 0.97 (0.078 to 1.20) 0.79
CRP‡ 66 – 0.94 (0.379 to 1.12) 0.51
Continued
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Variable N Category/term HR (95% CI) P value
Urea* 98 – 1.31 (1.03 to 1.67) 0.03
Na* 98 – 1.00 (0.73 to 1.38) 0.98
K 96 Linear term 1.45 (0.91 to 2.29) 0.03
Squared term 2.21 (1.09 to 4.49)
Creatinine§ 98 Linear term 0.71 (0.11 to 0.57) 0.006
Squared term 40 042 (9.2 to 1 768 852)
Total protein* 92 – 0.98 (0.83 to 1.17) 0.83
Albumin* 92 – 0.70 (0.55 to 0.88) 0.003
ALP§ 92 – 2.21 (0.70 to 6.98) 0.18
Adjusted calcium¶ 80 – 1.37 (1.10 to 1.70) 0.005
Phosphate¶ 77 – 0.92 (0.81 to 1.05) 0.21
Pleural fluid protein* 49 – 0.96 (0.80 to 1.13) 0.6
Pleural fluid LDH§ 52 – 4.26 (1.66 to 11.0) 0.003
For categorical predictor variables, the HRs give the risk of death in each category relative to the risk in a baseline category. For continuous 
predictor variables, the HRs give the relative change in the risk of death at any time for an increase in that variable.
*HRs reported for a 5- unit increase in variable.
†HRs reported for a 10- unit increase in variable.
‡HRs reported for a 50- unit increase in variable.
§Variable analysed on a log scale (base 10).
¶HRs reported for a 0.1- unit increase in variable.
Table 3 Continued
Table 4 Summary of the multivariate analysis results for 




term HR (95% CI) P value
Age at 
diagnosis*
– 1.31 (1.09 to 1.56) 0.004
Smoking 
status
Non- smoker 1 0.03
Ex- smoker 2.16 (1.09 to 1.56)
Current 
smoker
3.42 (1.11 to 4.20)
Chest pain No 1 0.007
Yes 2.14 (1.23 to 3.72)
Weight loss No 1 0.01
Yes 2.13 (1.18 to 3.86)
PLT† Linear term 1.05 (0.91 to 1.20) 0.01
Squared term 1.05 (1.00 to 1.10)
Urea* – 2.73 (1.31 to 5.69) 0.008
Adjusted 
calcium‡
– 1.47 (1.10 to 1.94) 0.008
*HRs reported for a 5- unit increase in variable.
†HRs reported for a 50- unit increase in variable.
‡HRs reported for a 0.1- unit increase in variable.
model, based on data from 74 patients, is summarised 
in table 4.
The multivariate results suggest that the predictor vari-
ables of age (HR 1.31, 95% CI 1.09 to 1.56), smoking 
status (current smoker HR 3.42, 95% CI 1.11 to 4.20), 
chest pain (HR 2.14, 95% CI 1.23 to 3.72), weight loss 
(HR 2.13, 95% CI 1.18 to 3.72), platelet count (HR 
1.05, 95% CI 1.00 to 1.10), urea (HR 2.73, 95% CI 1.31 
to 5.69) and adjusted calcium (HR 1.47, 95% CI 1.10 to 
1.94) are independently associated with patient survival. 
After adjusting for the variables in the final model, there 
is no longer a significant effect of weight, performance 
status, dyspnoea, haemoglobin, potassium, creatinine or 
albumin on the outcome.
The univariate analysis suggests a non- linear rela-
tionship for age. However, after adjusting for the other 
factors, there was a steady increase in the risk of death 
with increased age: a 5- year increase in age was associated 
with a 31% increase in the risk of death.
Smoking status, while only of borderline significance 
in the univariate analysis, was found to be more strongly 
significant in the multivariate analysis. Ex- smokers and 
current smokers were at increased risk: the risk of death 
at any time was 3.4 times greater for current smokers and 
2.16 times greater for ex- smokers than for non- smokers.
As in the univariate analyses, in the multivariate anal-
ysis patients with chest pain and weight loss were both at 
increased risk with a 2.14 and 2.13 times greater risk of 
death at any time, respectively. Higher urea and adjusted 
calcium values were also associated with increased risk.
The HRs for platelet count were broadly similar to 
those observed in the univariate analyses.
development of a risk model to predict prognosis
Regression coefficients were then calculated for the risk 
model. These factors were used as they were found to be 
independently most significantly associated with patient 
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Table 5 Summary of the regression coefficients for chosen 
variables
Variable Coefficient









Table 6 Comparison of the predicted risk of death at 






deaths in 6 
months
Observed 
deaths at 6 
months
≤25% 23 13.8% 17.4%
26%–60% 25 37.9% 32.0%
>60% 26 83.6% 80.8%











≤25% 4 3.2 χ2=0.8
26%–60% 8 9.4 p=0.38
>60% 21 21.7   
survival. A summary of the regression coefficients for all 
variables in the final model are given in table 5.
results of the risk model
The discrimination of the model was examined using 
Harrell’s c- statistic: a c- statistic value of 0.76 for this 
dataset suggests the model has some ability to discrim-
inate between low- risk and high- risk patients. Patients 
were split into one of three groups based on their 
predicted risk of death within 6 months. A comparison 
of the predicted risk of death at 6 months and the actual 
observed occurrence of death at 6 months was made, and 
the results are summarised in table 6.
The results demonstrate that the percentage of deaths 
predicted at 6 months increased proportionally with 
increased risk group, suggesting that the model has 
good discrimination. The actual percentage of observed 
deaths at 6 months was similar to the predicted values, 
demonstrating good calibration.
The Hosmer- Lemeshow test was also used to examine 
the calibration of the model in terms of the predicted 
cases of death within 6 months. A summary of the 
observed and predicted number of deaths is shown in 
table 7 along with the results of the test.
The non- significant result suggests good agreement 
between observed and predicted numbers of cases of 
death at 6 months for each of the risk groups. Thus, this 
result suggests a good calibration of the model.
dIscussIon
This was a retrospective analysis of potential prognostic 
factors in patients newly diagnosed with MPM. These 
factors were then used to develop a risk prediction model 
for death at 6 months. We identified age, smoking status, 
symptoms of chest pain and weight loss at presentation, 
and raised platelet count, urea and creatinine, as markers 
of poor prognosis in MPM.
The demographics of our patient cohort broadly 
reflect those of patients with MPM diagnosed within 
the UK during this period,19 with a similar average age 
at diagnosis and strong male predominance. However, 
1- year survival was lower than that seen nationally (26% 
vs 40%). Variation in survival between different centres 
has previously been recognised,5 and may be explained 
by performance status and comorbidity.
clinical variables
The data from this study demonstrated a steady increase 
in the risk of death from MPM with increasing age. Age is 
widely accepted as a significant determinant of life expec-
tancy. However, age in determining prognosis in patients 
in mesothelioma has been contentious. Although studies 
have previously reported age as a significant variable,20–22 
there are studies that suggest age has no prognostic 
significance.8
This study also found that smoking status was of value 
in predicting risk of mortality at 6 months. The multi-
variate analysis showed smoking to be significantly asso-
ciated with increased risk of death in both ex- smokers 
and current smokers. Previous studies have similarly not 
found a significant association between smoking status 
and prognosis in univariate analysis9 15; however, smoking 
status was consequently omitted from multivariate anal-
ysis in these studies. It is also possible that smoking status 
is a surrogate for other comorbid factors relating to prog-
nosis which were not recorded elsewhere in the database.
Chest pain and weight loss were associated with poorer 
outcomes. Few studies have previously examined a direct 
correlation between baseline symptoms and prognosis in 
patients with MPM, with conflicting evidence in this area: 
studies have previously demonstrated no significant asso-
ciation between weight loss and survival,6 although one 
study has demonstrated an association between weight 
loss at diagnosis and survival at 18 months.11 Chest pain is 
likely to reflect tumour invasion and is a surrogate marker 
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for cancer stage, whereas weight loss is a modifiable vari-
able that can be directly addressed. A study examining 
quality of life in patients with MPM identified pain as a 
symptom significantly associated with worse global quality 
of life,22 and further work in this field has identified that 
baseline quality of life is a significant prognostic factor 
for survival.23 24 An American study evaluating the role 
of early specialist symptom control delivered by palliative 
care specialists in advanced lung cancer reported better 
quality of life and improved survival.25 This work has iden-
tified an as- yet unmet need for research investigating the 
benefits of better symptom control on improving survival 
in mesothelioma.
Surprisingly, variables such as performance status, 
histological subtype and patient gender which in 
previous literature have been associated with prognostic 
outcome14 21 26 27 were not found to be significant. It is 
possible that in some cases, patients with suspected 
MPM and worse performance states may not have been 
included in the database as their frailty may have limited 
the ability to confirm diagnosis of MPM. This may explain 
why performance status, which is generally accepted as a 
strong predictor of mortality, was not significantly associ-
ated with risk of death in this study. Similarly, since some 
histological subtypes have previously been associated 
with rapid decline in performance status, it is possible 
that frailty in patients with more aggressive histological 
subtypes limited the ability to confirm a diagnosis of 
MPM and thus were not included in the database. While 
reflective of the demographic of patients diagnosed with 
MPM, it is possible the small size of the female cohort 
influenced the strength of the association with gender.
biochemical variables
Certain routine biochemical markers act as a surrogate for 
the patient’s overall condition, as a reflection of systemic 
illness. Studies have previously demonstrated the value of 
routine laboratory tests in predicting mortality in other 
pulmonary diseases, such as chronic obstructive pulmo-
nary disease.28 However, to date there has been limited 
data available on routinely available biochemical varia-
bles in mesothelioma.
Previous work has showed certain cancer types 
including mesothelioma to produce large amounts of 
interleukin-6 (IL-6)29 30 which are strongly correlated 
with platelet count, suggesting that IL-6 may have a role 
in tumour- associated thrombocytosis.29 Data on platelet 
count as a predictor of survival are conflicting, with some 
evidence showing no prognostic relevance.31 However, 
two more recent studies showed a significant association 
with higher platelet counts and poorer survival15 16; this 
was also demonstrated in our study, although the effect 
in the multivariate analysis was small.
The multivariate analysis identified elevated serum 
urea and calcium to be associated with an increased risk 
of death at 6 months. While there are limited data on 
urea as a prognostic marker for mesothelioma, a recent 
retrospective analysis of 114 patients also identified 
elevated serum urea to be a predictor of poor outcome17 
which is supportive of our findings.
A limitation to this work is that, as with many other 
studies evaluating prognosis, analysis was tested on a retro-
spective population, thus limiting the quality of evidence. 
Another shortcoming was the proportion of missing data 
encountered for certain variables, attributed to the retro-
spective nature of the study, resulting in their exclusion 
from analysis; for example, BMI and pleural fluid data.
conclusIon
In summary, we have developed a model to predict risk 
of death at 6 months in patients with a confirmed diag-
nosis of MPM using variables readily available in clin-
ical practice, derived from an unselected population at 
diagnosis. Although these factors alone cannot be used 
in isolation to predict prognosis, their presence may 
provide clinical teams with additional information when 
discussing life expectancy with patients and their fami-
lies. Further validation of the model requires evaluation 
of its performance on a separate dataset, which we intend 
to do with data from a recently completed national study 
(RESPECT- Meso7).
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